Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
STAT Summit
STAT+

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

By STAT StaffJan. 31, 2020

Reprints
Daniel O'Day STAT Summit
Gilead CEO Daniel O'Day Emilie Pickering for STAT

What’s Gilead going to buy?

That’s the single, persistent question Daniel O’Day has faced in his first months on the job as CEO of Gilead Sciences. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

STAT Staff

Tags

‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4…
‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
Vote now in STAT Madness 2023
Vote now in STAT Madness 2023
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…
A new Medicare ruling could give virtual reality companies…
A new Medicare ruling could give virtual reality companies an easier path to payment
8 burning questions Bernie Sanders and other senators should…
8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel

Recommended Stories